Skip to content

Axepharma

Active
Private limited company·Detailhandel in farmaceutische producten· 6 yrs active
Beverhoutsveldstraat 64 ·8730 Beernem, Belgium
KBO/BCE: BE 0739.549.477
Watch Print / PDF
Age6 yrs
Real estate2 parcels · 973 m²

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of Axepharma is 1.7% (moderate). The 2025 annual accounts show equity of €310k and a net result of €66k. The company has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 2 annual accounts.

Filing behaviour

From the deposit records, complete market-wide
Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-05-2026, 66 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
How we compute the deadline
The year end is derived from 6 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 26-05-2026 66 d early 2026-00120809
31-12-2024 31-07-2025 01-07-2025 30 d early 2025-00209307
31-12-2023 31-07-2024 31-07-2024 on the day 2024-00321999
31-12-2022 31-07-2023 07-08-2023 7 d late 2023-00319863
31-12-2021 31-07-2022 28-07-2022 3 d early 2022-20236399
31-12-2020 31-07-2021 22-07-2021 9 d early 2021-38800475

Source: the National Bank's deposit records, as we have ingested them. NOTE: our copy has a gap across June to August 2026, missing roughly 220,000 deposits; for July we hold 15,605 of about 137,000 expected. A year whose deadline falls in that window shows as not confirmed, not as not filed. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
More than 3 years active
Founded in 2019, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
1.7% Moderate
0%0,5%1,5%4%10%≥25%
Young company +Higher-failure-rate sector +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated or micro schema)
EBIT marginNot published (abbreviated or micro schema)
Net result€66k+12.8%
Working capital€303k-0.7%

Annual accounts & ratios

Source: NBB · 2025
Annual accounts filed on 26-05-2026 with the NBB · fiscal year 2025 · abbreviated schema
€0€25k€50k€75k€100kOperating result 2024: €86k€86kNet result 2024: €58k€58kOperating result 2025: €96k€96kNet result 2025: €66k€66k20242025
Operating resultNet result
EBITDA
€98k
+11.2% 24-25
Net profit
€66k
+12.8% 24-25
Cash flow
€68k
+11.9% 24-25
Total assets
€442k
+13.7% 24-25
Equity
€310k
+0.1% 24-25
Working capital
€303k
-0.7% 24-25
Employees (FTE)
1
-45.0% 24-25
Staff costs
€49k
-6.1% 24-25
Show 11 other metrics
Income taxes
€17k
+8.1% 24-25
Dividends
€63k
- 24-25
Debt
€132k
+67.3% 24-25
Debt ≤ 1y
€130k
+69.1% 24-25
Current ratio
3.32
-33.0% 24-25
Quick ratio
2.28
-31.1% 24-25
Solvency
70.1%
-12.0% 24-25
Debt / equity
0.43
+67.1% 24-25
ROE
21.2%
+12.7% 24-25
ROA
14.8%
-0.8% 24-25
Interest coverage
6.94
+8.1% 24-25
Figures by fiscal year
Fiscal year2025
Depositabbreviated schema
Revenue-
EBITDA€98k
Net profit€66k
Cash flow€68k
Staff costs€49k
Income taxes€17k
Dividends€63k
Total assets€442k
Equity€310k
Debt€132k
of which ≤ 1y€130k
of which > 1y-
Working capital€303k
Employees (FTE)1.1
Ratios (computed)
2025
Current ratio3.32
Quick ratio2.28
Working capital ratio68.6%
Solvency70.1%
Debt / equity0.43
Long-term debt ratio-
Interest coverage6.94
Gross margin-
Net margin-
ROA14.8%
ROE21.2%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€442k
Fixed assets 21/28€8k
Tangible fixed assets 22/27€8k
Financial fixed assets 28€200
Current assets 29/58€434k
Stocks & contracts in progress 3€136k
Amounts receivable within one year 40/41€104k
Cash & bank 54/58€178k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€442k
Equity 10/15€310k
Contributions / capital 10/11€10k
Reserves 13€300k
Amounts payable 17/49€132k
Amounts payable within one year 42/48€130k
Trade debts payable within one year 44€41k
Income statement
Gross operating margin 9900€152k
Operating result 9901€96k
Financial income 75€1k
Financial charges 65€14k
Result before taxes 9903€83k
Income taxes 67/77€17k
Net result for the period 9904€66k
Result to be appropriated 9905€66k
This table shows the latest fiscal year. 1 prior year, with figures and ratios, belongs to a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2025 · computed
100 / 100 Excellent
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

on the map · from the address register
exact location from the address register On OpenStreetMap
2 companies at this address See who is registered here

Establishment units

1 location
Axepharma
Smedenstraat 73, 8000 BruggeOverige kleinhandel in voedings- en genotmiddelen in gespecialiseerde winkels, n.e.g.
since 20192.296.535.970
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels2
Ground area973 m²
Buildings2
Building footprint323 m²
Volume (LiDAR)1,656 m³
Tallest building12.8 m · ±4 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 2 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
31021G0511/00E000 Flanders 891 m² 1 · 241 m² 7.6 m · 1 fl.
31804D1566/00B000 Flanders 82 m² 1 · 81 m² 12.8 m · 4 fl.
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Financial profile

5 of 5 axes measured
Health100Profitability100Solvency100Growth78Stability100
96 / 100

Exceptional profile, strong across almost every axis.

All 5 axes are computed from data Checked has read.

Health 100
Profitability 100
Solvency 100
Growth 78
Stability 100

Credit advice

verdict per customer and amount

May this customer buy amount X on invoice? Enter the amount and the payment term. This page computes a GREEN, AMBER or RED verdict from them, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector and region
We hold no filed accounts for this company, so a size comparison is not possible. These companies share only the sector and the region. We hold annual accounts for 499 of the 5,225 companies in this sector.

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Detailhandel in farmaceutische producten47730
Primary activity highlighted.
Names & trade names
Legal nameNL Axepharma
Registered office
Beverhoutsveldstraat 64
8730 Beernem, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.